How to use mavacamten

Mavacamten is primarily indicated for the treatment of adult patients with New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve function and symptoms. Before using drug treatment, it is necessary to confirm that women of reproductive potential are not pregnant and are using effective contraceptive methods. It is not recommended to start or increase the dose of CAMZYOS in patients with left ventricular ejection fraction (LVEF)<55%.

The recommended starting dose of Mavacartide is 5 mg orally once daily, without regard to food; permitted subsequent doses are 2.5 mg, 5 mg, 10 mg, or 15 mg orally once daily. The maximum recommended dose is 15 mg orally once daily. Swallow capsule whole. Do not break, open or chew capsules. Daily dosing takes several weeks to achieve steady-state drug levels and therapeutic effects, and genetic variation in metabolism and drug interactions can lead to large differences in exposure.

Patients may develop heart failure while taking MAVACARTA. Periodic evaluation of LVEF and Valsalva left ventricular outflow tract (LVOT) gradient is required to enable careful titration to achieve an appropriate target Valsalva LVOT gradient while maintaining LVEF ≥50% and avoiding symptoms of heart failure. When initiating or titrating Valsalva, consider first LVEF and then Valsalva LVOT gradient and patient clinical status to guide the appropriate dose of Valsalva. Initiate and maintain appropriate mavacartide dosage and monitoring schedule according to algorithm.

If LVEF is less than 50% while taking Mavakatai, interrupt treatment. Follow the Interrupt Algorithm for guidance on interrupting, restarting or stopping Mavakite. If interrupted at 2.5mg, it will either restart at 2.5mg or be permanently interrupted.

For patients on stable therapy with a weak CYP2C19 inhibitor or a moderate CYP3A4 inhibitor, take the recommended starting dose of 5 mg orally once daily. For patients starting a weak CYP2C19 inhibitor or a moderate CYP3A4 inhibitor, reduce the dose of mavacartide by one level (i.e., 15 mg → 10 mg; 10 mg → 5 mg; or 5 mg → 2.5 mg). For use with 2.5 mg of MavacetaIn patients who are stable on treatment, avoid concurrent use of weak CYP2C19 and moderate CYP3A4 inhibitors because lower once-daily doses of MAVACARTA are not available.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=669c936b-3ee6-4e36-8a22-79dd11b1255b##